Evidence map›Paper›PMID 40116211›Full record

ArticleProtein science : a publication of the Protein Society2025

Comparison of enriched charge variants from different anti-CD3 bispecific antibodies reveals differential susceptibility of each bispecific arm to post-translational modification.

Jennifer B Nguyen, Sophia Liu, Dylan A Howie, Zachary R Oberholtzer, Eric T Ong, Ramya Rao, Jethro E Prinston, Igor Dikiy, Jikang Wu, Zhijie Wu and 11 more

Abstract readComparative Study
In one paragraph

Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jennifer B NguyenProtein Biochemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.ORCID 0009-0008-0488-353X
Sophia LiuProtein Biochemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Dylan A HowieProtein Biochemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Zachary R OberholtzerProtein Biochemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Eric T OngProtein Biochemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Ramya RaoProtein Biochemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Jethro E PrinstonProtein Biochemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Igor DikiyProtein Biochemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Jikang WuAnalytical Chemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Zhijie WuAnalytical Chemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Yimeng ZhaoAnalytical Chemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Meinuo LiAnalytical Chemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Rosalynn MoldenAnalytical Chemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Guido MolinaTherapeutic Proteins, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Kathleen ProvonchaTherapeutic Proteins, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Cristinel SanduTherapeutic Proteins, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Haibo QiuAnalytical Chemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Ning LiAnalytical Chemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
William MatousekProtein Biochemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Michael P RosconiProtein Biochemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Erica A PylesProtein Biochemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Charge heterogeneity is an important quality attribute of therapeutic antibodies, and a detailed understanding of charge heterogeneity arising from post-translational modifications (PTMs) is required by regulatory agencies during drug development. Among antibody therapeutics, the bispecific antibody with two distinct Fab domains targeting distinct antigens provides additional complexity to the charge profile. In this study, charge variant species were enriched from three bispecific antibodies (bsAbs) each containing one anti-CD3 binding arm designed with differential affinity to CD3. The charge heterogeneity corresponding to each anti-CD3 arm within each enriched fraction was evaluated using a domain-specific, digestion-assisted imaged capillary isoelectric focusing (icIEF) method known as DiCE. Through fractionation, we observed that the anti-CD3 arm of each bispecific antibody exhibited different distributions of acidic variants, even when the anti-CD3 arms were identical based on primary sequence. Reduced peptide mapping was performed on specific fractions to identify unique site-specific PTMs that were uncovered or enriched through fractionation. In each case, the bispecific arm that was most susceptible to PTMs exhibited a more basic isoelectric point. Conformational stability analysis of each bispecific antibody using differential scanning calorimetry suggested that the more basic Fab arm tended to be correlated with a lower melting temperature, although it is unclear the extent to which PTMs on the basic arm may contribute to reduced conformational stability. Overall, these results provide additional evidence that each of the two arms of a bispecific antibody may exhibit differential susceptibility to post-translational modification and that this susceptibility is likely correlated with subtle differences in overall bispecific antibody structure, which is influenced by electrostatic properties inherent to the primary sequence. Future studies to obtain high-resolution structures of full-length bispecific antibodies by crystallography or cryo-electron microscopy may help to elucidate the driving force for susceptibility to PTMs in bispecific antibodies.

Indexed as

Antibodies, BispecificCD3 ComplexProtein Processing, Post-TranslationalHumansAntibodies, BispecificCD3 Complexanalytical characterizationbispecific antibodiesCD3imaged capillary isoelectric focusingpost‐translational modification

Identifiers

PMID40116211
PMCPMC11926628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.